TrimRx's Blog

Semaglutide doesn’t treat addiction, but may reduce cravings in recovery by modulating dopamine pathways. Here’s what the research shows and doesn’t.

Semaglutide shows emerging neuroprotective effects in Parkinson’s research. Early trials suggest GLP-1 receptor activity may slow motor symptom

Semaglutide shows 40-70% reduction in Alzheimer’s risk across multiple trials. Mechanisms, dosing, and what patients need to know about GLP-1

Semaglutide smoking cessation shows emerging evidence for reducing nicotine cravings through GLP-1 receptor mechanisms affecting dopamine reward pathways

Semaglutide 2 year results show 10–15% sustained weight loss in clinical trials. Long-term data reveals maintenance patterns, side effects, and metabolic

Semaglutide reduces lean mass 25–40% of total weight loss, compromising power-to-weight ratios and recovery. Athletes need structured protocols.

Semaglutide alters body composition during powerlifting by reducing muscle glycogen and strength output — here’s how to train effectively while on GLP-1s.

Semaglutide 5 year results show sustained weight loss averaging 10–15% when maintained, but two-thirds regain weight within one year of stopping — here’s

Semaglutide affects endurance, recovery, and fueling strategies for triathletes — here’s what the research shows about training on GLP-1 medications.